Evidence map›Paper›PMID 24871545›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2014

In vivo amphetamine action is contingent on αCaMKII.

Thomas Steinkellner, Liudmilla Mus, Birgit Eisenrauch, Andreea Constantinescu, Damiana Leo, Lisa Konrad, Mattias Rickhag, Gunnar Sørensen, Evgenia V Efimova, Eryan Kong and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.5field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Persistent binding at dopamine transporters determines sustained psychostimulant effects.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  8. Article
  9. Methamphetamine Dysregulation of the Central Nervous System and Peripheral Immunity.The Journal of pharmacology and experimental therapeutics · 2021
    Review
  10. Article
  11. Article
  12. Effects of nicotine on DARPP-32 and CaMKII signaling relevant to addiction.Advances in pharmacology (San Diego, Calif.) · 2021
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Deletion ofEMBO reports · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 4 countries.

Thomas SteinkellnerInstitute of Pharmacology, Center for Physiology and Pharmacology, Medical University Vienna, Waehringer Strasse, Vienna, Austria.
Liudmilla Mus1] Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia (IIT), Via Morego, Genova, Italy [2] Department of Psychopharmacology, Institute of Pharmacology, Pavlov Medical University, St Petersburg, Russia.ORCID 0000000275887617
Birgit EisenrauchInstitute of Pharmacology, Center for Physiology and Pharmacology, Medical University Vienna, Waehringer Strasse, Vienna, Austria.
Andreea ConstantinescuInstitute of Pharmacology, Center for Physiology and Pharmacology, Medical University Vienna, Waehringer Strasse, Vienna, Austria.
Damiana LeoDepartment of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia (IIT), Via Morego, Genova, Italy.
Lisa KonradInstitute of Pharmacology, Center for Physiology and Pharmacology, Medical University Vienna, Waehringer Strasse, Vienna, Austria.ORCID 0000000187253139
Mattias RickhagMolecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience and Pharmacology, Faculty of Health and Medical Sciences, The Panum Institute, University of Copenhagen, Copenhagen, Denmark.
Gunnar SørensenMolecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience and Pharmacology, Faculty of Health and Medical Sciences, The Panum Institute, University of Copenhagen, Copenhagen, Denmark.
Evgenia V EfimovaSkolkovo Institute of Science and Technology (Skoltech), Skolkovo, Moscow, Russia.
Eryan KongDepartment of Neurophysiology and Neuropharmacology, Center for Physiology and Pharmacology, Medical University Vienna, Waehringer Strasse, Vienna, Austria.
Matthäus WilleitDepartment of Psychiatry and Psychotherapy, Medical University of Vienna, Waehringer Guertel, Vienna, Austria.
Tatyana D SotnikovaDepartment of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia (IIT), Via Morego, Genova, Italy.
Oliver KudlacekInstitute of Pharmacology, Center for Physiology and Pharmacology, Medical University Vienna, Waehringer Strasse, Vienna, Austria.
Ulrik GetherMolecular Neuropharmacology and Genetics Laboratory, Department of Neuroscience and Pharmacology, Faculty of Health and Medical Sciences, The Panum Institute, University of Copenhagen, Copenhagen, Denmark.
Michael FreissmuthInstitute of Pharmacology, Center for Physiology and Pharmacology, Medical University Vienna, Waehringer Strasse, Vienna, Austria.
Daniela D PollakDepartment of Neurophysiology and Neuropharmacology, Center for Physiology and Pharmacology, Medical University Vienna, Waehringer Strasse, Vienna, Austria.
Raul R Gainetdinov1] Department of Neuroscience and Brain Technologies, Istituto Italiano di Tecnologia (IIT), Via Morego, Genova, Italy [2] Skolkovo Institute of Science and Technology (Skoltech), Skolkovo, Moscow, Russia [3] Faculty of Biology and Soil Science, St Petersburg State University, St Petersburg, Russia.
Harald H SitteInstitute of Pharmacology, Center for Physiology and Pharmacology, Medical University Vienna, Waehringer Strasse, Vienna, Austria.
Medical University of Vienna · ATUniversity of Copenhagen · DKItalian Institute of Technology · ITSkolkovo Institute of Science and Technology · RUFirst Pavlov State Medical University of St. Petersburg · RU

Funding

STRUCTURE/FUNCTION OF THE HUMAN DOPAMINE TRANSPORTERP01DA012408 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI WEINSTEIN, HAREL · 1999 to 2015
$14.2M
Austrian Science Fund FWF W 1232NIDA NIH HHS P01 DA012408
6 · The paper itself

Abstract

Addiction to psychostimulants (ie, amphetamines and cocaine) imposes a major socioeconomic burden. Prevention and treatment represent unmet medical needs, which may be addressed, if the mechanisms underlying psychostimulant action are understood. Cocaine acts as a blocker at the transporters for dopamine (DAT), serotonin (SERT), and norepinephrine (NET), but amphetamines are substrates that do not only block the uptake of monoamines but also induce substrate efflux by promoting reverse transport. Reverse transport has been a focus of research for decades but its mechanistic basis still remains enigmatic. Recently, transporter-interacting proteins were found to regulate amphetamine-triggered reverse transport: calmodulin kinase IIα (αCaMKII) is a prominent example, because it binds the carboxyl terminus of DAT, phosphorylates its amino terminus, and supports amphetamine-induced substrate efflux in vitro. Here, we investigated whether, in vivo, the action of amphetamine was contingent on the presence of αCaMKII by recording the behavioral and neurochemical effects of amphetamine. Measurement of dopamine efflux in the dorsal striatum by microdialysis revealed that amphetamine induced less dopamine efflux in mice lacking αCaMKII. Consistent with this observation, the acute locomotor responses to amphetamine were also significantly blunted in αCaMKII-deficient mice. In addition, while the rewarding properties of amphetamine were preserved in αCaMKII-deficient mice, their behavioral sensitization to amphetamine was markedly reduced. Our findings demonstrate that amphetamine requires the presence of αCaMKII to elicit a full-fledged effect on DAT in vivo: αCaMKII does not only support acute amphetamine-induced dopamine efflux but is also important in shaping the chronic response to amphetamine.

Indexed as

AnimalsCalcium-Calmodulin-Dependent Protein Kinase Type 2Central Nervous System StimulantsConditioning, PsychologicalCorpus StriatumDextroamphetamineDisks Large Homolog 4 ProteinDopamineGuanylate KinasesHyperkinesisLocomotionMaleMembrane ProteinsMice, Inbred C57BLMice, KnockoutReceptors, DopamineCalcium-Calmodulin-Dependent Protein Kinase Type 2Camk2a protein, mouseCentral Nervous System StimulantsDextroamphetamineDisks Large Homolog 4 ProteinDlg4 protein, mouseDopamineGuanylate KinasesMembrane ProteinsReceptors, Dopamine

Identifiers

PMID24871545
PMCPMC4207348
OpenAlexW2044384081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.